BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16190753)

  • 1. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
    Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
    J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
    Leftheris K; Ahmed G; Chan R; Dyckman AJ; Hussain Z; Ho K; Hynes J; Letourneau J; Li W; Lin S; Metzger A; Moriarty KJ; Riviello C; Shimshock Y; Wen J; Wityak J; Wrobleski ST; Wu H; Wu J; Desai M; Gillooly KM; Lin TH; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Zhang R; Diller D; Doweyko A; Sack J; Baldwin J; Barrish J; Dodd J; Henderson I; Kanner S; Schieven GL; Webb M
    J Med Chem; 2004 Dec; 47(25):6283-91. PubMed ID: 15566298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
    Liu C; Lin J; Wrobleski ST; Lin S; Hynes J; Wu H; Dyckman AJ; Li T; Wityak J; Gillooly KM; Pitt S; Shen DR; Zhang RF; McIntyre KW; Salter-Cid L; Shuster DJ; Zhang H; Marathe PH; Doweyko AM; Sack JS; Kiefer SE; Kish KF; Newitt JA; McKinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    J Med Chem; 2010 Sep; 53(18):6629-39. PubMed ID: 20804198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
    de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA
    J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.
    Lumeras W; Vidal L; Vidal B; Balagué C; Orellana A; Maldonado M; Domínguez M; Segarra V; Caturla F
    J Med Chem; 2011 Nov; 54(22):7899-910. PubMed ID: 21999461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzothiazole based inhibitors of p38alpha MAP kinase.
    Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
    J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
    Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
    Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
    J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
    Das J; Chen P; Norris D; Padmanabha R; Lin J; Moquin RV; Shen Z; Cook LS; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; McIntyre KW; Shuster DJ; Gillooly KM; Behnia K; Schieven GL; Wityak J; Barrish JC
    J Med Chem; 2006 Nov; 49(23):6819-32. PubMed ID: 17154512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.
    Angell R; Aston NM; Bamborough P; Buckton JB; Cockerill S; deBoeck SJ; Edwards CD; Holmes DS; Jones KL; Laine DI; Patel S; Smee PA; Smith KJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4428-32. PubMed ID: 18614366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase.
    Cumming JG; McKenzie CL; Bowden SG; Campbell D; Masters DJ; Breed J; Jewsbury PJ
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5389-94. PubMed ID: 15454232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
    Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
    J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
    Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.